Currently, Indoramin has become a topic of great relevance and interest for different areas of society. From academia to business, Indoramin has captured the attention of many people due to its impact and relevance today. Technological and social advances have contributed to the growth and importance of Indoramin in contemporary life, which has generated endless debates, discussions and analyzes around this topic. That is why this article will address in detail and critically the importance of Indoramin today, as well as its influence on different aspects of modern life.
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.043.659 |
Chemical and physical data | |
Formula | C22H25N3O |
Molar mass | 347.462 g·mol−1 |
3D model (JSmol) | |
| |
|
Indoramin (trade names Baratol and Doralese) is a piperidine antiadrenergic agent.
It is an alpha-1 selective adrenoceptor antagonist with direct myocardial depression action; therefore, it results in no reflex tachycardia. It is also used in benign prostatic hyperplasia (BPH).
It is commonly synthesized from tryptophol.
Indoramin is commonly prescribed as 20 mg tablets when used in BPH.
Drowsiness, dizziness, dry mouth, nasal congestion, headache, fatigue, weight gain, hypotension, postural hypotension, depression, problems with ejaculation, diarrhoea, nausea, increased need to pass urine, and palpitations.
Tryptamine and serotonin are naturally occurring indole ethylamino compounds with pronounced pharmacological activities. They have served as the inspiration for synthesis of numerous analogues.
One such study involved alkylation of 4-benzamidopyridine (2) with a bromoethyy compound (1) derived from tryptophol, to give a quaternary pyridinium salt (3); this intermediate was in turn hydrogenated with a Raney nickel catalyst to give indoramine.
On May 31, 2013, the French National Agency for the Safety of Medicines and Health Products (ANSM) concluded that the benefit/risk ratio of this product was unfavorable and withdrew Vidora's marketing authorization and recalled its batches from the market on June 3, 2013.